Epsilogen
ID: 12489560Developer of immunoglobulin E (IgE) antibodies to treat cancer.
7
Funding Rounds
$117.3m
Money raised
Recent Funding Rounds
Overview
Developer of immunoglobulin E (IgE) antibodies to treat cancer.
- Website:
- Business model: B2B
- Headquarters: London
- Social accounts: linkedin
Unlock Complete Company Intelligence
Access comprehensive data and insights available only to Seedtable members
Financial Details
- • Complete funding history and valuations
- • Revenue estimates and financial metrics
- • Investment round details and terms
People & Contacts
- • Complete leadership team profiles
- • Contact information and email addresses
- • Board members and advisors
Market Intelligence
- • Competitive landscape analysis
- • Market position and growth metrics
- • Industry benchmarking data
Premium Tools
- • Export data and generate reports
- • Save companies to custom watchlists
- • API access for data integration
Join 10,000+ Professionals
Trusted by investors, founders, and analysts worldwide
Access detailed insights on 71,000+ companies worldwide
Funding
Funding series
Funding Series Analysis
The company Epsilogen has raised a total of $117.3m in funding over 7 rounds.
Key Insights:
- Epsilogen Series B Round, September 2024: $16.5m
- Epsilogen Series B round, March 2022: $41.2m
- Epsilogen February 2022 Funding Round: $42m
- Epsilogen November 2018 Series A Funding Round: $6.3m
- Epsilogen November 2018 Series A Funding Round: $6.3m
- Epsilogen June 2017 Series A Funding Round: $2.5m
- Epsilogen June 2017 Series A Funding Round: $2.5m
Industries
Epsilogen is active in the following industries: